OMER Overview

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.

Wall Street analysts forecast OMER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is43.67 USD with a low forecast of 36.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Omeros Corp revenue for the last quarter amounts to 9.89M USD, decreased

Omeros Corp. EPS for the last quarter amounts to 0.62 USD, decreased -206.90

Omeros Corp (OMER) has 175 emplpoyees as of June 19 2026.

Today OMER has the market capitalization of 744.02M USD.